ASLAN Pharmaceuticals – $42 Million IPO
Shanghai – June 8, 2018 – Cooley advised ASLAN Pharmaceuticals Limited on its $42 million initial public offering of 6,000,000 American Depositary Shares, each representing five ordinary shares. Cooley partners Patrick Loofbourrow, Charlie Kim, Rob Phillips, Sean Clayton and Dave Peinsipp led the team advising Aslan.
Leerink Partners and Piper Jaffray acted as joint book-running managers for the offering. BTIG, H.C. Wainwright & Co. and CLSA acted as co-managers for the offering.
This IPO marks the first Taipei Exchange-listed company to go public in the US. The ADSs now trade on the Nasdaq Global Market under the symbol “ASLN” and the ordinary shares have traded on the Tapei Exchange since Q2 2017 under the symbol “6497.”
ASLAN is a Singapore clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. Aslan targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.
This complex, precedent-setting transaction leverages Cooley’s strengths in the capital markets and life sciences sectors across Asia and the US.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.